Content
01/28/2025
Boston, MA USA
Atalanta Therapeutics
completed $97 million Series B Round funding. Investors include
Sanofi Ventures (lead), EQT Ventures (lead), RiverVest Venture Partners, Novartis Venture Fund, abrdn, Pictet Group, Mirae Asset Venture Investment, F-Prime Capital.
About
Atalanta Therapeutics is a biotechnology company developing treatments for intractable diseases of the central nervous system using RNA interference. Atalanta’s unique platform of divalent small interfering RNA (di-siRNA) enables durable, selective gene silencing throughout the brain and spinal cord. Atalanta is advancing a wholly owned pipeline of disease-modifying programs for Huntington’s disease, genetic epilepsy, severe chronic pain, and other neurological diseases in addition to partnered programs as part of a strategic collaboration with Genentech. Atalanta is headquartered in Boston, Mass.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
